Joana  Azeredo

Prof. Dr. Joana Azeredo

Centre of Biological Engineering, University of Minho, Braga, Portugal
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2016 in Critical Reviews in Microbiology
Verified
Journal Article
Open access
JAJoana Azeredo
Joana Azeredo
Nuno AzevedoNuno Azevedo
Nuno Azevedo
Romain BriandetRomain Briandet
Romain Briandet
NCNuno Cerca
Nuno Cerca
TCTom Coenye
Tom Coenye
CSClaus Sternberg
Claus Sternberg
Biofilms are widespread in nature and constitute an important strategy implemented by microorganisms to survive in sometimes harsh environmental conditions. They can be beneficial or have a negative impact particularly when formed in industrial settings or on medical devices. As such, research into the formation and elimination of biofilms is important for many disciplines. Several new methodologies have been recently developed for, or adapted to, biofilm studies that have contributed to deeper knowledge on biofilm physiology, structure and composition. In this review, traditional and cutting-edge methods to study biofilm biomass, viability, structure, composition and physiology are addressed. Moreover, as there is a lack of consensus among the diversity of techniques used to grow and study biofilms. This review intends to remedy this, by giving a critical perspective, highlighting the advantages and limitations of several methods. Accordingly, this review aims at helping scientists in finding the most appropriate and up-to-date methods to study their biofilms.

1 March 2012 in FEMS Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
SSSónia Silva
Sónia Silva
MNMelyssa Negri
Melyssa Negri
MHMaria Henriques
Maria Henriques
RORosário Oliveira
Rosário Oliveira
DWDavid W. Williams
David W. Williams
JAJoana Azeredo
Joana Azeredo

21 December 2015 in Critical Reviews in Microbiology
Verified
Journal Article
Closed access
PDF file
Bruna GonçalvesBruna Gonçalves
Bruna Gonçalves
CFCarina Ferreira
Carina Ferreira
CACarlos Tiago Alves
Carlos Tiago Alves
MHMaria Henriques
Maria Henriques
JAJoana Azeredo
Joana Azeredo
SSSónia Silva
Sónia Silva
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. . ???aop.label???. doi: 10.3109/1040841X.2015.1091805

15 January 2016 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
DPDiana Pires
Diana Pires
Hugo OliveiraHugo Oliveira
Hugo Oliveira
Luís D. R. MeloLuís D. R. Melo
Luís D. R. Melo
Sanna SillankorvaSanna Sillankorva
Sanna Sillankorva
JAJoana Azeredo
Joana Azeredo

1 September 2016 in Microbiology and Molecular Biology Reviews
Verified
Journal Article
Open access
PDF file
DPDiana Pires
Diana Pires
SCSara Cleto
Sara Cleto
Sanna SillankorvaSanna Sillankorva
Sanna Sillankorva
JAJoana Azeredo
Joana Azeredo
TLTimothy K. Lu
Timothy K. Lu
SUMMARY Soon after their discovery in the early 20th century, bacteriophages were recognized to have great potential as antimicrobial agents, a potential that has yet to be fully realized. The nascent field of phage therapy was adversely affected by inadequately controlled trials and the discovery of antibiotics. Although the study of phages as anti-infective agents slowed, phages played an important role in the development of molecular biology. In recent years, the increase in multidrug-resistant bacteria has renewed interest in the use of phages as antimicrobial agents. With the wide array of possibilities offered by genetic engineering, these bacterial viruses are being modified to precisely control and detect bacteria and to serve as new sources of antibacterials. In applications that go beyond their antimicrobial activity, phages are also being developed as vehicles for drug delivery and vaccines, as well as for the assembly of new materials. This review highlights advances in techniques used to engineer phages for all of these purposes and discusses existing challenges and opportunities for future work.

29 August 2014 in mBio
Verified
Journal Article
Open access
PDF file
YBYves Briers
Yves Briers
MWMaarten Walmagh
Maarten Walmagh
VPVictor Van Puyenbroeck
Victor Van Puyenbroeck
ACAnneleen Cornelissen
Anneleen Cornelissen
WCWilliam Cenens
William Cenens
Rob LavigneRob Lavigne
Rob Lavigne
The global threat to public health posed by emerging multidrug-resistant bacteria in the past few years necessitates the development of novel approaches to combat bacterial infections. Endolysins encoded by bacterial viruses (or phages) represent one promising avenue of investigation. These enzyme-based antibacterials efficiently kill Gram-positive bacteria upon contact by specific cell wall hydrolysis. However, a major hurdle in their exploitation as antibacterials against Gram-negative pathogens is the impermeable lipopolysaccharide layer surrounding their cell wall. Therefore, we developed and optimized an approach to engineer these enzymes as outer membrane-penetrating endolysins (Artilysins), rendering them highly bactericidal against Gram-negative pathogens, including Pseudomonas aeruginosa and Acinetobacter baumannii . Artilysins combining a polycationic nonapeptide and a modular endolysin are able to kill these (multidrug-resistant) strains in vitro with a 4 to 5 log reduction within 30 min. We show that the activity of Artilysins can be further enhanced by the presence of a linker of increasing length between the peptide and endolysin or by a combination of both polycationic and hydrophobic/amphipathic peptides. Time-lapse microscopy confirmed the mode of action of polycationic Artilysins, showing that they pass the outer membrane to degrade the peptidoglycan with subsequent cell lysis. Artilysins are effective in vitro (human keratinocytes) and in vivo ( Caenorhabditis elegans ). IMPORTANCE Bacterial resistance to most commonly used antibiotics is a major challenge of the 21st century. Infections that cannot be treated by first-line antibiotics lead to increasing morbidity and mortality, while millions of dollars are spent each year by health care systems in trying to control antibiotic-resistant bacteria and to prevent cross-transmission of resistance. Endolysins—enzymes derived from bacterial viruses—represent a completely novel, promising class of antibacterials based on cell wall hydrolysis. Specifically, they are active against Gram-positive species, which lack a protective outer membrane and which have a low probability of resistance development. We modified endolysins by protein engineering to create Artilysins that are able to pass the outer membrane and become active against Pseudomonas aeruginosa and Acinetobacter baumannii , two of the most hazardous drug-resistant Gram-negative pathogens.